Conference Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 174 - Patient Centricity at the Heart of Innovative Trial Design
Type: Invited
Date/Time: Monday, August 8, 2022 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #320651
Title: The Predictive Individual Effect for Survival Data
Author(s): Kannan Natarajan*
Companies: Pfizer
Keywords: Patient-centered Measure; Time-to-event endpoint; Non-proportional hazards; Prediction; Survival Gain; Bayesian
Abstract:

The call for patient-focused drug development is loud and clear, as expressed in the 21st Century Cures Act and in recent regulatory guidelines and initiatives. Among the factors contributing to modernized drug development and improved healthcare are easily interpretable measures of clinical benefit. Special care is needed for cancer trials with time-to-event endpoints, especially if the proportional hazards assumption is questionable. In addition to hypothesis testing and estimation of hazard ratios and median survival times, we propose the predictive individual effect as a more tangible measure of clinical benefit. It uses the data from the actual trial to quantify a new patient's potential survival gain, that is, the difference between the patient’s predicted survival times under the test and control treatment. The predictive individual effect has a clear and simple interpretation. The usefulness of the new measure is illustrated with four examples from recent Oncology trials.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2022 program